Present investigation includes development of dry powder for inhalation of pDNA loaded PEGylated composite nanoparticles of PLGA and Polyethylenimine to treat cystic fibrosis. Nanoparticles were developed by using double emulsion solvent evaporation method. Further nanoparticles were converted into dry powder for inhalation using freeze drying method. In vitro cell line studies were carried out to find out the safety and efficacy of the formulations. In vitro lung deposition studies and in vivo animal studies were also carried out to confirm the effectiveness and safety of developed dry powder formulation in treatment of cystic fibrosis.
